| Noncontrolling Interest Disclosure [Text Block] |
| 20. | Non-controlling interests |
The following are majority-owned subsidiaries of the Company and the percentage of ownership interest maintained by the Company is set forth in the parenthetical: Enroot (75%), Aphria Diamond (51%), and Colcanna S.A.S. (90%).
Summarized balance sheet information of the entities in which there is a non-controlling interest as of May 31, 2026:
| | | | | | | Aphria | | | ColCanna | | | May 31, | |
| | | Enroot | | | Diamond | | | S.A.S. | | | 2026 | |
| Current assets | | $ | 201 | | | $ | 110,664 | | | $ | 1 | | | $ | 110,866 | |
| Non-current assets | | | — | | | | 105,278 | | | | 3,756 | | | | 109,034 | |
| Current liabilities | | | (4 | ) | | | (129,883 | ) | | | (7,147 | ) | | | (137,034 | ) |
| Non-current liabilities | | | — | | | | (38,231 | ) | | | (1,440 | ) | | | (39,671 | ) |
| Net assets | | $ | 197 | | | $ | 47,828 | | | $ | (4,830 | ) | | $ | 43,195 | |
Summarized balance sheet information of the entities in which there is a non-controlling interest as of May 31, 2025:
| | | SH | | | CC Pharma | | | Aphria | | | ColCanna | | | May 31, | |
| | | Acquisition | | | Nordic ApS | | | Diamond | | | S.A.S. | | | 2025 | |
| Current assets | | $ | — | | | $ | — | | | $ | 83,390 | | | $ | 20 | | | $ | 83,410 | |
| Non-current assets | | | — | | | | — | | | | 114,677 | | | | 3,348 | | | | 118,025 | |
| Current liabilities | | | — | | | | — | | | | (126,986 | ) | | | (6,953 | ) | | | (133,939 | ) |
| Non-current liabilities | | | — | | | | — | | | | (31,720 | ) | | | (1,442 | ) | | | (33,162 | ) |
| Net assets | | $ | — | | | $ | — | | | $ | 39,361 | | | $ | (5,027 | ) | | $ | 34,334 | |
On January 7, 2025, the Company dissolved its 75% ownership interest in CC Pharma Nordic ApS., and as a result, the Company no longer controls CC Pharma Nordic ApS. and thus no longer consolidates this entity.
On January 16, 2025, MedMen exited receivership and substantially all of its remaining assets were transferred to a new entity owned by MedMen’s secured creditors, including SH Acquisition. In connection with this restructuring, the Company disposed of its MedMen Convertible Note in exchange for on option to acquire a 68% membership interest in SH Acquisition for $1.00 upon U.S. federal cannabis legalization. As a result, the Company no longer controls SH Acquisition and thus no longer consolidates this entity.
Summarized income statement information of the entities in which there is a non-controlling interest for the fiscal year ended May 31, 2026:
| | | | | | | Aphria | | | ColCanna | | | May 31, | |
| | | Enroot | | | Diamond | | | S.A.S. | | | 2026 | |
| Revenue | | $ | 29 | | | $ | 81,477 | | | $ | — | | | $ | 81,506 | |
| Total expenses | | | 39 | | | | 48,459 | | | | (622 | ) | | | 47,876 | |
| Net (loss) income | | | (10 | ) | | | 33,018 | | | | 622 | | | | 33,630 | |
| Other comprehensive (loss) income | | | — | | | | 2,899 | | | | (425 | ) | | | 2,474 | |
| Net comprehensive (loss) income | | $ | (10 | ) | | $ | 35,917 | | | $ | 197 | | | $ | 36,104 | |
| Non-controlling interest % | | | 25 | % | | | 49 | % | | | 10 | % | | NA | |
| Comprehensive (loss) income attributable to NCI | | | (3 | ) | | | 17,599 | | | | 20 | | | | 17,616 | |
| Additional income attributable to NCI | | | — | | | | — | | | | — | | | | - | |
| Net comprehensive (loss) income attributable to NCI | | $ | (3 | ) | | $ | 17,599 | | | $ | 20 | | | $ | 17,616 | |
Summarized income statement information of the entities in which there is a non-controlling interest for the fiscal year ended May 31, 2025:
| | | SH | | | CC Pharma | | | Aphria | | | ColCanna | | | May 31, | |
| | | Acquisition | | | Nordic ApS | | | Diamond | | | S.A.S. | | | 2025 | |
| Revenue | | $ | — | | | $ | — | | | $ | 78,414 | | | $ | — | | | $ | 78,414 | |
| Total expenses | | | 20,000 | | | | 11 | | | | 54,274 | | | | 290 | | | | 74,575 | |
| Net (loss) income | | | (20,000 | ) | | | (11 | ) | | | 24,140 | | | | (290 | ) | | | 3,839 | |
| Other comprehensive (loss) income | | | — | | | | 8 | | | | (45 | ) | | | (12 | ) | | | (49 | ) |
| Net comprehensive (loss) income | | $ | (20,000 | ) | | $ | (3 | ) | | $ | 24,095 | | | $ | (302 | ) | | $ | 3,790 | |
| Non-controlling interest % | | | 32 | % | | | 25 | % | | | 49 | % | | | 10 | % | | NA | |
| Comprehensive (loss) income attributable to NCI | | | (6,400 | ) | | | (1 | ) | | | 11,807 | | | | (30 | ) | | | 5,376 | |
| Additional income attributable to NCI | | | — | | | | — | | | | — | | | | — | | | | — | |
| Net comprehensive (loss) income attributable to NCI | | $ | (6,400 | ) | | $ | (1 | ) | | $ | 11,807 | | | $ | (30 | ) | | $ | 5,376 | |
Summarized income statement information of the entities in which there is a non-controlling interest for the fiscal year ended May 31, 2024:
| | | SH | | | CC Pharma | | | Aphria | | | ColCanna | | | May 31, | |
| | | Acquisition | | | Nordic ApS | | | Diamond | | | S.A.S. | | | 2024 | |
| Revenue | | $ | — | | | $ | — | | | $ | 103,331 | | | $ | — | | | $ | 103,331 | |
| Total expenses | | | 42,681 | | | | (1,064 | ) | | | 40,935 | | | | (203 | ) | | | 82,349 | |
| Net (loss) income | | | (42,681 | ) | | | 1,064 | | | | 62,396 | | | | 203 | | | | 20,982 | |
| Other comprehensive (loss) income | | | — | | | | (9 | ) | | | 171 | | | | (334 | ) | | | (172 | ) |
| Net comprehensive (loss) income | | $ | (42,681 | ) | | $ | 1,055 | | | $ | 62,567 | | | $ | (131 | ) | | $ | 20,810 | |
| Non-controlling interest % | | | 32 | % | | | 25 | % | | | 49 | % | | | 10 | % | | NA | |
| Comprehensive (loss) income attributable to NCI | | | (13,658 | ) | | | 264 | | | | 30,658 | | | | (13 | ) | | | 17,251 | |
| Additional income attributable to NCI | | | — | | | | — | | | | 5,336 | | | | — | | | | 5,336 | |
| Net comprehensive (loss) income attributable to NCI | | $ | (13,658 | ) | | $ | 264 | | | $ | 35,994 | | | $ | (13 | ) | | $ | 22,587 | |
|